Last update:

HIV & AIDS news

HIV & AIDS

Early HIV drugs give immune system a brief reprieve before dysregulation returns, study finds

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.

HIV & AIDS

Low-dose THC may reduce side effects of HIV treatment

Long-term, low doses of THC mitigate many harmful side effects and inflammation caused by HIV and antiretroviral therapy (ART), according to new research from Texas Biomedical Research Institute.

HIV & AIDS

Early HIV treatment: Research reveals critical gaps

In an article published in The Lancet HIV, authors including Distinguished Professor Denis Nash and Professor Constantin Yiannoutsos aim to provide the most comprehensive estimates of pediatric mortality among children and ...

HIV & AIDS

How HIV disrupts sleep across Africa

HIV significantly affects sleep, with many affected people living in a state akin to chronic jet lag. A new study with Wits researchers published in The Lancet HIV describes how people living with HIV (PLWHIV) experience ...

Genetics

COVID-19 genetic risk variant protects against HIV

The genetic variants we are born with can increase or decrease our risk of falling seriously ill with COVID-19. The major genetic risk variant for severe COVID-19, one we inherited from Neandertals, is surprisingly common. ...

HIV & AIDS

New 'highly virulent' HIV strain discovered in the Netherlands

Oxford researchers announced Thursday the discovery of a highly virulent strain of HIV that has been lurking in the Netherlands for decades, but because of the effectiveness of modern treatments, is "no cause for alarm."

HIV & AIDS

Tracking cells that host HIV

New research sheds light on the lifespans and location of the cells that are responsible for producing HIV, preventing its eradication. Understanding the cells' dynamics may help scientists develop new ways to reduce their ...

Medications

Promising results of Phase 1 drug trial for HIV patients

A Phase 1 clinical trial conducted by University of Minnesota researchers has demonstrated the safety and efficacy of a novel immunotherapy drug in the treatment of human immunodeficiency virus (HIV). Results of the trial ...

Medications

Long-acting cabotegravir not necessarily cost-effective for PrEP

(HealthDay)—For men who have sex with men and transgender women (MSM/TGW) at very high risk for HIV (VHR), the benefits of long-acting injectable cabotegravir (CAB-LA) in terms of life expectancy do not necessarily justify ...

Oncology & Cancer

Study finds cancer immunotherapy treatment can reverse HIV latency

An international research collaboration has found the cancer immunotherapy treatment, pembrolizumab, can reverse HIV latency, the ability for the virus to 'hide' inside cells of people living with HIV on antiretroviral therapy, ...

HIV & AIDS

Men who paid for sex more likely than other men to live with HIV

Twenty years' worth of surveys suggest that nearly one in ten sexually active men in 35 countries in sub-Saharan Africa have been clients of sex workers, and these men are about 50 percent more likely to be living with human ...